Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 16 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding its tentative approval from the USFDA for Sugammadex Injection. The approval allows Zydus Pharmaceuticals (USA) Inc. to market the injection, which is used to reverse neuromuscular blockade during surgery. The drug will be produced at the company's manufacturing facility in Jarod, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases